Apollomics: Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

  Apollomics Inc. (Nasdaq: APLM) (the “Company”), today announced a report by the Veneto Institute of Oncology on the efficacy response of a patient treated with vebreltinib for GBM with PTPRZ-MET fusion, at the European Society of Medical Oncology Congress (ESMO) 2023, held in Madrid, Spain from October 20-24, 2023.

The patient with GBM with PTPRZ-MET fusion who had previously received radiotherapy and temozolomide, was reported to have an impressive Partial Response (PR) after 8 weeks of treatment with vebreltinib monotherapy during participation in the SPARTA study (NCT03175224).

https://www.globenewswire.com/news-release/2023/10/26/2767559/0/en/Apollomics-Announces-Report-of-Activity-of-Vebreltinib-in-Glioblastoma-Multiforme-GBM-with-PTPRZ-MET-Fusion.html